Lixte Biotechnology Holdings Inc Warrants (01/01/2025) LIXTW 深 滬
等待開盤 09-20 09:30:00 美东时间
0.025
-0.013
-34.21%
華盛通- 最 高0.038
- 今 開0.038
- 成交量 926股
- 最 低 0.025
- 昨 收 0.038
- 總市值 33.85万
- 52周最高 0.11
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.019
- 委 比 -48.70%
- 總股本 1353.83万
- 歷史最高 6.77
- 量 比 0.05
- 振 幅 34.21%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多快讯 | lixte biotechnology 提供了最近活动和发展的更新。
Lixte Biotechnology Provides Update on Recent Activities and Developments
08-19 20:30
快讯 | lixte biotechnology：与荷兰癌症研究所达成临床试验协议。
Lixte Biotechnology: Got Into Clinical Trial Agreement With Netherlands Cancer ...
06-14 20:37
快讯 | lixte biotechnology: 对于转移性结肠癌患者，与Atezolizumab联合应用Lb-100进行1B/2期临床试验的协议
Lixte Biotechnology: Agreement to Conduct a Phase 1B/2 Clinical Trial of Lb-100...
06-14 20:37
Lixte Biotechnology Appoints New Chief Medical Officer
An announcement from Lixte Biotechnology Holdings (LIXT) is now available. In a...
06-06 05:04
Lixte Biotechnology appoints Jan Schellens as CMO
LIXTE Biotechnology Holdings(NASDAQ:LIXT) has announced the appointment of Jan Schellens, M.D., Ph.D., as CMO. He assumes the CMO role at LIXTE effective Aug. 1, 2024, succeeding James S. Miser, M.D.,...
06-03 22:21
快讯 | Lixte Biotechnology授予著名肿瘤学家Jan Schellens博士担任首席医疗官
Lixte Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Ch...
06-03 20:30
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on "Therapeutic Over-Activation in Cancer"
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Present...
05-08 21:25
Lixte stock soars on preclinical data for lead drug LB-100
Shares of Lixte Biotechnology (NASDAQ:LIXT) were up nearly 60% in afternoon trading Wednesday after the company reported the publication of positive preclinical data for its lead clinical asset LB-100...
03-28 02:43
Why Lixte Biotechnology Stock Is Soaring
The company announced the publication of pre-clinical data in the online journal, "Cancer Discovery", showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled "Paradoxical activation of oncogenic signaling as a cancer treatment strategy."
03-27 22:56
Lixte Biotechnology Granted U.S. Patent # 11866444: Oxabicycloheptane prodrugs
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11866444
01-09 18:36
